Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle. It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems. In addition, the company offers biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; transportation of frozen biological specimens to and from customer locations; and management of incoming and outgoing biological specimens, as well as provides logistics support and management; and short-term logistics and engineering consulting services. It serves biopharma/pharma, animal health, and human reproductive medicine markets. The company was founded in 1999 and is headquartered in Brentwood, Tennessee.
Analysts Set New Price Targets
CYRX has been the topic of several recent analyst reports. Needham & Company LLC boosted their target price on Cryoport from $41.00 to $42.00 and gave the stock a "buy" rating in a research report on Tuesday, July 12th. Roth Capital decreased their price target on Cryoport from $90.00 to $67.00 in a research note on Tuesday, May 3rd. KeyCorp decreased their price target on Cryoport from $92.00 to $52.00 in a research note on Friday, May 6th. B. Riley decreased their price target on Cryoport from $61.00 to $55.00 in a research note on Tuesday, May 17th. Finally, BTIG Research decreased their price target on Cryoport from $95.00 to $60.00 in a research note on Friday, May 6th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $61.33.
Cryoport Price Performance
CYRX Stock traded up $1.40 on Friday, reaching $45.00. The company had a trading volume of 452,019 shares, compared to its average volume of 521,845. Cryoport has a 1 year low of $19.82 and a 1 year high of $86.30. The company has a debt-to-equity ratio of 0.73, a quick ratio of 13.69 and a current ratio of 14.21. The company's fifty day moving average is $32.51 and its 200 day moving average is $31.39. The company has a market cap of $2.18 billion, a P/E ratio of -7.13 and a beta of 1.13.
Cryoport (NASDAQ:CYRX - Get Rating) last posted its earnings results on Thursday, August 4th. The consumer goods maker reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.08). Cryoport had a negative net margin of 125.96% and a negative return on equity of 14.43%. The company had revenue of $64.20 million during the quarter, compared to analysts' expectations of $64.58 million. During the same period in the previous year, the company posted ($0.16) EPS. Cryoport's quarterly revenue was up 14.2% compared to the same quarter last year. On average, research analysts forecast that Cryoport will post -0.8 earnings per share for the current year.